Data from 42 studies 4-6, 12, 27-37, 39-46, 49, 50, 53-57, 64-68, 72-78 were pooled for meta-analysis of elevated ALT levels in COVID-19 patients, resulting in prevalence of 19% (95% CI: 0.16, 0.23; Figure 3). This evidence concerns the gene GPT and COVID-19.